South Korea Medical Morphine Market

What is theSouth Korea Medical Morphine Market Size?

As per the survey report on South Korea medical morphine market, the market is expected to foresee a CAGR value of XX% during 2026-2036, and further generate a market size of USD XX billion by the end of 2036. In 2025, the market size was value at USD XX billion revenue.

• The South Korea medical morphine market’s growth is driven by rising prevalence of chronic pain conditions.
• KDMI analyst’s growth analysis foresees stringent regulatory controls as restraint for South Korea medical morphine market.
• In the South Korea medical morphine market, application segment is playing significant role.

South Korea Medical Morphine Market Analysis

Morphine is a potent opioid (narcotic) medication used to treat severe, chronic pain that cannot be managed by other medicines. They are derived from the opium poppy, and works by binding to opioid receptors in the brain and central nervous system to alter pain perception. The South Korea medical morphine market is experiencing significant growth due to increasing prevalence of chronic pain conditions, driven by growing recognition of the importance of effective pain management. According to the data, South Korea’s elderly population has reached 20.6% in 2025 and is estimated to grow by 46.4% by 2070. Due to rapidly aging population, managing chronic pain in older adults has become essential due to its severe impacts. The prevalence of acute and chronic pain was 73.5% in 2021. Moreover, innovations in medical devices and medications have further propelled market growth.

South Korea Medical Morphine Market Growth Drivers and Restraints

Growth Drivers

• Rising prevalence of chronic pain conditions – The rising incidence of chronic pain-related conditions in Sout Korea is driving demand for medical morphine. Disorders such as cancer, musculoskeletal diseases, and neurological conditions are becoming more common across the country due to rapidly aging population. According to reports, irregular working hours have severe side effects on occupational health. Musculoskeletal disorders are important disease group in occupational health, accounting for 56.8% of occupational diseases in 2021. Furthermore, overall opioid consumption has gained traction in the country, with increasing prescription rates across all age groups, particularly among elderly. This results in growing need for clinically-effective pain management solutions, contributing significantly to the sustained market growth of medical morphine.
• Increasing surgical procedures – Another key factor driving market expansion is growing volume of surgical procedures in South Korea, particularly in perioperative and post-operative care. According to a Medical Report, the number of cataract surgeries were performed in the country was 638,000, making it highest among 34 major surgeries. Total surgical medical expenses amounted to 8.44 trillion, accounting for an increase of 4.4% from 2023. Moreover, the growing adoption of advanced surgical techniques, including robotic and minimally invasive procedures, is further increasing surgical throughput and complexity, thereby elevating the need for effective pain control solutions. As surgical procedures continue to expand across both elective and critical care segments, the demand for opioid analgesics like morphine remains strong to ensure adequate pain management and patient recovery outcomes.

Restraints

• Stringent regulatory controls on opioid use - Stringent regulations on opioid prescription and distribution to prevent misuse and addition creates expansion challenges. These controls enhance patient safety, but also restricts widespread prescribing, thereby limiting overall market growth.
• Risk of side effects – Morphine is associated with severe adverse effects such as respiratory depression, nausea, constipation, and risk of addiction. Therefore, increasing awareness about its side-effects among healthcare professionals and patients are leading to cautious use. This encourages significant shift toward safer alternatives, thereby restraining market growth.

South Korea Medical Morphine Market Segmentation

Our experts at KD Market Insights have segmented the South Korea medical morphine market research report as:

Analyst’s Observation on South Korea Medical Morphine Market Recent Developments

Over the years, the experts at KD Market Insights have been observing the recent developments associated with South Korea medical morphine market trends. Our expert’s market forecast analysis has recorded the market players adopting plentiful of key strategies including new product launches, mergers & acquisitions, and collaborations.

VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj, has received approval from the Ministry of Food and Drug Safety (MFDS). UNAFRA Inj., discovered by using the company's proprietary multi-target drug development platform, is the world's first non-opioid, non-NSAIDS analgesic. It induces analgesic effect by simultaneously inhibiting Glycine Transporter Type 2 (GlyT2) and Serotonin Receptor 2a (5HT2a).

South Korea Medical Morphine Market Competitive Landscape

Some of the significant participants who the South Korea medical morphine market growth:

• Mallinckrodt Pharmaceuticals
• Alcaliber S.A
• Sanofi
• Johnson Matthey
• Northeast Pharmaceutical Group Co., Ltd
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc
• Cipla Inc
• Mylan N.V.
• Fresenius Kabi USA
• DAIICHI SANKYO COMPANY
• Allergan
• Pacira BioSciences, Inc.